Back to Search
Start Over
Hemodynamic performance of self-expandable transcatheter aortic valve replacement systems during valve deployment.
- Source :
-
The Journal of invasive cardiology [J Invasive Cardiol] 2024 Aug; Vol. 36 (8). - Publication Year :
- 2024
-
Abstract
- Objectives: Little is known about valve hemodynamic performance during the Evolut and Neo deployment course. We aimed to evaluate transvalvular mean and peak-to-peak gradients over several intraprocedural timepoints during TAVR with Evolut PRO+ (Medtronic) and Neo (Boston Scientific) systems.<br />Methods: This was single-center pilot sub-study from the SavvyWire EFficacy and SafEty in Transcatheter Aortic Valve Implantation Procedures (SAFE-TAVI) trial. Participants received either the Evolut PRO+ or Neo for native valve severe aortic stenosis and the SavvyWire (OpSens Medical) was used for device delivery, pacing, and continuous left ventricular and aortic pressure measurements. For the Evolut, evaluation was done for baseline, two-thirds of valve deployment (still recapturable), 90% of valve deployment (no longer recapturable), and post-deployment hemodynamics. For the Neo, analysis was done at baseline, after the first step (top-crown deployment), and at final status.<br />Results: Nineteen patients were included (Evolut = 15; Neo = 4). There were no statistically significant changes in peak-to-peak gradients (44 mm Hg [IQR:33-69] vs 43 mm Hg [IQR:26-62], P = .41) between baseline and two-thirds of valve deployment in the Evolut patients. There was a significant decrease in mean (40 mm Hg [IQR:32-54] vs 14 mm Hg [IQR:10-18], P less than .001) and peak-to-peak (43 mmHg [IQRS:26-62] vs 9 mm Hg [IQR:8-13], P less than .001) transvalvular gradients between two-thirds and 90% of valve deployment for Evolut. Neo patients exhibited a decrease in transvalvular gradients after top-crown deployment (42.5 mm Hg baseline vs 13 mm Hg).<br />Conclusions: Transvalvular gradients did not vary between the point of "no-recapture" compared to baseline values in patients receiving the Evolut, whereas a significant reduction in transvalvular gradients was observed when the valve was deployed at 90% and fully deployed. The Neo valve was slightly obstructive after the first step of deployment.
- Subjects :
- Humans
Male
Female
Aged, 80 and over
Treatment Outcome
Pilot Projects
Aged
Follow-Up Studies
Transcatheter Aortic Valve Replacement methods
Transcatheter Aortic Valve Replacement adverse effects
Aortic Valve Stenosis surgery
Aortic Valve Stenosis physiopathology
Aortic Valve Stenosis diagnosis
Hemodynamics physiology
Prosthesis Design
Heart Valve Prosthesis
Aortic Valve surgery
Aortic Valve physiopathology
Subjects
Details
- Language :
- English
- ISSN :
- 1557-2501
- Volume :
- 36
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- The Journal of invasive cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 38489568
- Full Text :
- https://doi.org/10.25270/jic/23.00286